Adage Capital Partners GP L.L.C. bought a new position in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 157,618 shares of the company's stock, valued at approximately $7,261,000. Adage Capital Partners GP L.L.C. owned approximately 0.56% of Establishment Labs as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds have also made changes to their positions in ESTA. R Squared Ltd acquired a new position in Establishment Labs in the fourth quarter valued at $36,000. KLP Kapitalforvaltning AS acquired a new position in Establishment Labs in the 4th quarter valued at about $161,000. Hood River Capital Management LLC increased its position in Establishment Labs by 236.4% in the 4th quarter. Hood River Capital Management LLC now owns 5,920 shares of the company's stock valued at $273,000 after acquiring an additional 4,160 shares during the period. Handelsbanken Fonder AB raised its stake in Establishment Labs by 32.3% during the 4th quarter. Handelsbanken Fonder AB now owns 8,200 shares of the company's stock valued at $378,000 after acquiring an additional 2,000 shares during the last quarter. Finally, SkyView Investment Advisors LLC lifted its position in Establishment Labs by 30.5% during the 3rd quarter. SkyView Investment Advisors LLC now owns 12,000 shares of the company's stock worth $519,000 after acquiring an additional 2,805 shares during the period. 72.91% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several equities research analysts have recently commented on ESTA shares. Needham & Company LLC initiated coverage on Establishment Labs in a research note on Monday, April 14th. They set a "hold" rating for the company. Stephens restated an "overweight" rating and set a $52.00 price objective on shares of Establishment Labs in a research report on Thursday, March 6th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $57.40.
Read Our Latest Stock Report on ESTA
Establishment Labs Price Performance
Shares of Establishment Labs stock traded up $2.35 during trading on Friday, reaching $33.39. The company's stock had a trading volume of 572,721 shares, compared to its average volume of 461,604. The business has a 50 day moving average price of $35.67 and a 200-day moving average price of $38.83. Establishment Labs Holdings Inc. has a 12-month low of $26.56 and a 12-month high of $60.12. The company has a market capitalization of $963.17 million, a P/E ratio of -12.94 and a beta of 0.77. The company has a quick ratio of 2.29, a current ratio of 3.62 and a debt-to-equity ratio of 5.94.
Establishment Labs (NASDAQ:ESTA - Get Free Report) last issued its earnings results on Wednesday, February 26th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.34). The company had revenue of $44.51 million for the quarter, compared to analysts' expectations of $44.45 million. Establishment Labs had a negative return on equity of 184.55% and a negative net margin of 46.13%. As a group, sell-side analysts anticipate that Establishment Labs Holdings Inc. will post -2.41 EPS for the current year.
About Establishment Labs
(
Free Report)
Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.
Further Reading
Before you consider Establishment Labs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Establishment Labs wasn't on the list.
While Establishment Labs currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
